Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Iovance Biotherapeutics (IOVA) Shares Outstanding (2016 - 2025)

Iovance Biotherapeutics has reported Shares Outstanding over the past 13 years, most recently at $194.0 for Q4 2025.

  • Quarterly results put Shares Outstanding at $194.0 for Q4 2025, down 100.0% from a year ago — trailing twelve months through Dec 2025 was $194.0 (down 100.0% YoY), and the annual figure for FY2025 was $194.0, down 100.0%.
  • Shares Outstanding for Q4 2025 was $411.9 million at Iovance Biotherapeutics, up from $385.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding for IOVA hit a ceiling of $411.9 million in Q4 2025 and a floor of $194.0 in Q1 2023.
  • Median Shares Outstanding over the past 3 years was $276.7 million (2023), compared with a mean of $216.1 million.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 1464929.9% in 2024 and later crashed 100.0% in 2025.
  • Iovance Biotherapeutics' Shares Outstanding stood at $256.1 million in 2023, then rose by 19.18% to $305.3 million in 2024, then crashed by 100.0% to $194.0 in 2025.
  • The last three reported values for Shares Outstanding were $194.0 (Q4 2025), $1.9 million (Q3 2025), and $194.0 (Q2 2025) per Business Quant data.